Review



proliferation medium  (PromoCell)


Bioz Verified Symbol PromoCell is a verified supplier
Bioz Manufacturer Symbol PromoCell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    PromoCell proliferation medium
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Proliferation Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 477 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proliferation medium/product/PromoCell
    Average 98 stars, based on 477 article reviews
    proliferation medium - by Bioz Stars, 2026-05
    98/100 stars

    Images

    1) Product Images from "Increased utrophin expression in healthy and DMD patient derived myoblasts in response to ERK1/2 and EZH2 inhibitor treatment"

    Article Title: Increased utrophin expression in healthy and DMD patient derived myoblasts in response to ERK1/2 and EZH2 inhibitor treatment

    Journal: bioRxiv

    doi: 10.64898/2026.04.13.718206

    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in proliferation media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Figure Legend Snippet: Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in proliferation media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.

    Techniques Used: Derivative Assay, Staining, Concentration Assay, Cell Culture, Cell Characterization, Control, Quantitative RT-PCR, Comparison



    Similar Products

    proliferation medium  (PromoCell)
    98
    PromoCell proliferation medium
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Proliferation Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proliferation medium/product/PromoCell
    Average 98 stars, based on 1 article reviews
    proliferation medium - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    medium  (PromoCell)
    98
    PromoCell medium
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/medium/product/PromoCell
    Average 98 stars, based on 1 article reviews
    medium - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    muscle biopsy  (PromoCell)
    98
    PromoCell muscle biopsy
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Muscle Biopsy, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/muscle biopsy/product/PromoCell
    Average 98 stars, based on 1 article reviews
    muscle biopsy - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    skeletal muscle cell growth medium  (PromoCell)
    98
    PromoCell skeletal muscle cell growth medium
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Skeletal Muscle Cell Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/skeletal muscle cell growth medium/product/PromoCell
    Average 98 stars, based on 1 article reviews
    skeletal muscle cell growth medium - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    growth medium  (PromoCell)
    98
    PromoCell growth medium
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/growth medium/product/PromoCell
    Average 98 stars, based on 1 article reviews
    growth medium - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    skeletal muscle cell growth medium 353  (PromoCell)
    98
    PromoCell skeletal muscle cell growth medium 353
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Skeletal Muscle Cell Growth Medium 353, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/skeletal muscle cell growth medium 353/product/PromoCell
    Average 98 stars, based on 1 article reviews
    skeletal muscle cell growth medium 353 - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    skeletal muscle cell growth medium kits  (PromoCell)
    98
    PromoCell skeletal muscle cell growth medium kits
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Skeletal Muscle Cell Growth Medium Kits, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/skeletal muscle cell growth medium kits/product/PromoCell
    Average 98 stars, based on 1 article reviews
    skeletal muscle cell growth medium kits - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in proliferation media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.

    Journal: bioRxiv

    Article Title: Increased utrophin expression in healthy and DMD patient derived myoblasts in response to ERK1/2 and EZH2 inhibitor treatment

    doi: 10.64898/2026.04.13.718206

    Figure Lengend Snippet: Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in proliferation media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.

    Article Snippet: The muscle biopsy was enzymatically digested in basal medium (C-23060; PromoCell, Heidelberg, Germany) containing collagenase D (2 mg/mL, Roche, Germany) and Dispase II (2 mg/mL, Sigma) for 1 h at 37°C with trituration every 15 min. After filtering through a 100-μm filter (BD Falcon) and centrifugation cells were resuspended in proliferation medium (15% FBS, C-23060; PromoCell, Heidelberg, Germany) and transferred to a T-25 tissue culture vessel (Nunc, Germany).

    Techniques: Derivative Assay, Staining, Concentration Assay, Cell Culture, Cell Characterization, Control, Quantitative RT-PCR, Comparison